

R E M A R K S

This is a Divisional Application of application Serial No. 09/167,151.

In the March 7, 2000 Office Action in parent application Serial No. 09/167,151, there was a Restriction Requirement under 35 USC 121 involving Groups I to IV. Group I was elected in response to said Restriction Requirement in application Serial No. 09/167,151. The claims in this Divisional application are directed to the claims of non-elected Groups II to IV.

The specification was editorially revised.

A MARKED UP VERSION OF THE AMENDMENTS TO THE SPECIFICATION is enclosed.

Also enclosed is a MARKED UP VERSION OF THE AMENDED CLAIMS.

New claims 89 and 90 contain features of original claim 62.

09/167,151-012301

Enclosed is a copy of the DECLARATION UNDER 37 CFR 1.132 of Dr. Tohru TAKAHASHI, dated December 15, 1997, the original of which was filed in grandparent application Serial No. 08/500,635.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
RSB/ddf

- Enclosures: (1) Replacement specification pages 127 to 140
of the Sequence Listing
- (2) MARKED UP VERSION OF THE AMENDMENTS TO THE
SPECIFICATION
- (3) MARKED UP VERSION OF THE AMENDED CLAIMS
- (4) Copy of DECLARATION UNDER 37 CFR 1.132
of Dr. Tohru TAKAHASHI, dated December 15, 1997

MARKED UP VERSION OF THE
AMENDMENTS TO THE SPECIFICATION

Paragraph bridging pages 12 and 13:

--The present invention will be illustrated with respect to the accompanying drawings, in which:

Figure 1 is a restriction enzyme map of cDNA of the NIa region isolated from CYVV-cDNA;

Figure 2 is a schematic drawing which shows the construction of plasmid pKNI5' containing a 5'-region of NIa;

Figure 3 is a schematic diagram which shows the construction of plasmid pKNI5IL containing a part of the IL-11 gene and a 5'-region of NIa;

Figure 4 is a schematic diagram which shows primers which were used to prepare the 5'IL DNA fragment, the CIN3 DNA fragment and in which the 3'-terminus of the NIa gene and the 5'-terminus of the IL-11 gene are fused;

Figure 5 is a schematic diagram which shows the fusion of the CIN3 DNA fragment and the [IL5'DNA] 5'IL DNA fragment by PCR;

Figure 6 is a schematic diagram which shows the construction of plasmid pKSUN9;

Figure 7 is a construction enzyme map of pUCKM31-7;

Figure 8 is a comparative diagram of the nucleotide sequences of the 3' terminals in pUCKM31-7 and pcD-31;

Figure 9 is a construction diagram of [pSR α 31-7]
pSR α 31-7;

Figure 10 is a schematic diagram [of] showing the introduction of a histidine hexamer encoding sequence into pUCKM31-7;

Figure 11 is a construction diagram [of] for pMAL31-7;

[Figure 12 is a diagram] Figures 12A and 12B are graphs showing
the results of the assay of dichlorophenol-indophenol reducing activity; and

Figure 13 is a graph showing the determination of oxidized glutathione reducing activity.--

Paragraph bridging pag s 99 and 100:

--The next step was to verify that the several specific 60 kDa bands identified in Example 11 are the same as the polypeptide encoded by the insert of pSR α 31-7. It was also desired to determine the N-terminal amino acid sequence of this polypeptide. Accordingly, a clone was prepared wherein an extra six His residues were encoded for the C-terminal of the polypeptide before the stop codon. Histidine residues have a high affinity for Ni^{2+} and the objective was to express a polypeptide having a histidine hexamer (6 x His), which could be purified using an affinity resin column charged with $[\text{Ni}^{2+}]$ Ni^{2+} .--

Paragraph bridging pages 105 and 106:

--90.4 μg , as determined using the Protein Assay Kit (Bio-Rad), of each of the chromatography samples obtained in ii) above were separately mixed with 1 ml of 50 μM DCIP (Sigma). 15 μl of 1 mM NADPH (Boehringer-Mannheim) were then added to each of the samples and the $\text{OD}_{600\text{nm}}$ and $\text{OD}_{340\text{nm}}$ absorbance values were monitored with time. The resulting decrease in absorbance at both wavelengths [as] is shown in [Figure 12] Figures 12A and 12B, and it can be seen that only the pMAL31-7 sample contains a factor that reduces DCIP.--

THE

1. NAME _____
 2. ADDRESS _____
 3. CITY _____
 4. STATE _____
 5. ZIP _____
 6. PHONE _____
 7. DATE _____
 8. SIGNATURE _____
 9. PRINT NAME _____
 10. PRINT ADDRESS _____
 11. PRINT CITY _____
 12. PRINT STATE _____
 13. PRINT ZIP _____
 14. PRINT PHONE _____
 15. PRINT DATE _____
 16. PRINT SIGNATURE _____
 17. PRINT NAME _____
 18. PRINT ADDRESS _____
 19. PRINT CITY _____
 20. PRINT STATE _____
 21. PRINT ZIP _____
 22. PRINT PHONE _____
 23. PRINT DATE _____
 24. PRINT SIGNATURE _____
 25. PRINT NAME _____
 26. PRINT ADDRESS _____
 27. PRINT CITY _____
 28. PRINT STATE _____
 29. PRINT ZIP _____
 30. PRINT PHONE _____
 31. PRINT DATE _____
 32. PRINT SIGNATURE _____
 33. PRINT NAME _____
 34. PRINT ADDRESS _____
 35. PRINT CITY _____
 36. PRINT STATE _____
 37. PRINT ZIP _____
 38. PRINT PHONE _____
 39. PRINT DATE _____
 40. PRINT SIGNATURE _____
 41. PRINT NAME _____
 42. PRINT ADDRESS _____
 43. PRINT CITY _____
 44. PRINT STATE _____
 45. PRINT ZIP _____
 46. PRINT PHONE _____
 47. PRINT DATE _____
 48. PRINT SIGNATURE _____
 49. PRINT NAME _____
 50. PRINT ADDRESS _____
 51. PRINT CITY _____
 52. PRINT STATE _____
 53. PRINT ZIP _____
 54. PRINT PHONE _____
 55. PRINT DATE _____
 56. PRINT SIGNATURE _____
 57. PRINT NAME _____
 58. PRINT ADDRESS _____
 59. PRINT CITY _____
 60. PRINT STATE _____
 61. PRINT ZIP _____
 62. PRINT PHONE _____
 63. PRINT DATE _____
 64. PRINT SIGNATURE _____
 65. PRINT NAME _____
 66. PRINT ADDRESS _____
 67. PRINT CITY _____
 68. PRINT STATE _____
 69. PRINT ZIP _____
 70. PRINT PHONE _____
 71. PRINT DATE _____
 72. PRINT SIGNATURE _____
 73. PRINT NAME _____
 74. PRINT ADDRESS _____
 75. PRINT CITY _____
 76. PRINT STATE _____
 77. PRINT ZIP _____
 78. PRINT PHONE _____
 79. PRINT DATE _____
 80. PRINT SIGNATURE _____
 81. PRINT NAME _____
 82. PRINT ADDRESS _____
 83. PRINT CITY _____
 84. PRINT STATE _____
 85. PRINT ZIP _____
 86. PRINT PHONE _____
 87. PRINT DATE _____
 88. PRINT SIGNATURE _____
 89. PRINT NAME _____
 90. PRINT ADDRESS _____
 91. PRINT CITY _____
 92. PRINT STATE _____
 93. PRINT ZIP _____
 94. PRINT PHONE _____
 95. PRINT DATE _____
 96. PRINT SIGNATURE _____
 97. PRINT NAME _____
 98. PRINT ADDRESS _____
 99. PRINT CITY _____
 100. PRINT STATE _____
 101. PRINT ZIP _____
 102. PRINT PHONE _____
 103. PRINT DATE _____
 104. PRINT SIGNATURE _____
 105. PRINT NAME _____
 106. PRINT ADDRESS _____
 107. PRINT CITY _____
 108. PRINT STATE _____
 109. PRINT ZIP _____
 110. PRINT PHONE _____
 111. PRINT DATE _____
 112. PRINT SIGNATURE _____
 113. PRINT NAME _____
 114. PRINT ADDRESS _____
 115. PRINT CITY _____
 116. PRINT STATE _____
 117. PRINT ZIP _____
 118. PRINT PHONE _____
 119. PRINT DATE _____
 120. PRINT SIGNATURE _____
 121. PRINT NAME _____
 122. PRINT ADDRESS _____
 123. PRINT CITY _____
 124. PRINT STATE _____
 125. PRINT ZIP _____
 126. PRINT PHONE _____
 127. PRINT DATE _____
 128. PRINT SIGNATURE _____
 129. PRINT NAME _____
 130. PRINT ADDRESS _____
 131. PRINT CITY _____
 132. PRINT STATE _____
 133. PRINT ZIP _____
 134. PRINT PHONE _____
 135. PRINT DATE _____
 136. PRINT SIGNATURE _____
 137. PRINT NAME _____
 138. PRINT ADDRESS _____
 139. PRINT CITY _____
 140. PRINT STATE _____
 141. PRINT ZIP _____
 142. PRINT PHONE _____
 143. PRINT DATE _____
 144. PRINT SIGNATURE _____
 145. PRINT NAME _____
 146. PRINT ADDRESS _____
 147. PRINT CITY _____
 148. PRINT STATE _____
 149. PRINT ZIP _____
 150. PRINT PHONE _____
 151. PRINT DATE _____
 152. PRINT SIGNATURE _____
 153. PRINT NAME _____
 154. PRINT ADDRESS _____
 155. PRINT CITY _____
 156. PRINT STATE _____
 157. PRINT ZIP _____
 158. PRINT PHONE _____
 159. PRINT DATE _____
 160. PRINT SIGNATURE _____
 161. PRINT NAME _____
 162. PRINT ADDRESS _____
 163. PRINT CITY _____
 164. PRINT STATE _____
 165. PRINT ZIP _____
 166. PRINT PHONE _____
 167. PRINT DATE _____
 168. PRINT SIGNATURE _____
 169. PRINT NAME _____
 170. PRINT ADDRESS _____
 171. PRINT CITY _____
 172. PRINT STATE _____
 173. PRINT ZIP _____
 174. PRINT PHONE _____
 175. PRINT DATE _____
 176. PRINT SIGNATURE _____
 177. PRINT NAME _____
 178. PRINT ADDRESS _____
 179. PRINT CITY _____
 180. PRINT STATE _____
 181. PRINT ZIP _____
 182. PRINT PHONE _____
 183. PRINT DATE _____
 184. PRINT SIGNATURE _____
 185. PRINT NAME _____
 186. PRINT ADDRESS _____
 187. PRINT CITY _____
 188. PRINT STATE _____
 189. PRINT ZIP _____
 190. PRINT PHONE _____
 191. PRINT DATE _____
 192. PRINT SIGNATURE _____
 193. PRINT NAME _____
 194. PRINT ADDRESS _____
 195. PRINT CITY _____
 196. PRINT STATE _____
 197. PRINT ZIP _____
 198. PRINT PHONE _____
 199. PRINT DATE _____
 200. PRINT SIGNATURE _____
 201. PRINT NAME _____
 202. PRINT ADDRESS _____
 203. PRINT CITY _____
 204. PRINT STATE _____
 205. PRINT ZIP _____
 206. PRINT PHONE _____
 207. PRINT DATE _____
 208. PRINT SIGNATURE _____
 209. PRINT NAME _____
 210. PRINT ADDRESS _____
 211. PRINT CITY _____
 212. PRINT STATE _____
 213. PRINT ZIP _____
 214. PRINT PHONE _____
 215. PRINT DATE _____
 216. PRINT SIGNATURE _____
 217. PRINT NAME _____
 218. PRINT ADDRESS _____
 219. PRINT CITY _____
 220. PRINT STATE _____

MARKED UP VERSION OF THE AMENDED CLAIMS

48. (Amended) A polypeptide having the sequence [given by]
consisting essentially of residue numbers 4 to 437 in [sequence]
SEQ ID [number] NO:2 [in the sequence listing].

55. (Amended) [The] A polypeptide [encoded by the
polynucleotide sequence of claim 49] which consists essentially
of amino acid numbers 1 to 526 of SEQ ID NO: 12, and which
catalyzes the reduction of dichloroindophenol and oxidized
glutathione.

60. (Amended) [The] A polypeptide [encoded by the
polynucleotide sequence of claim 54] having the sequence
consisting essentially of -23 to 526 of SEQ ID NO: 12.

61. (Amended) A method for the prophylaxis or treatment of
conditions caused by, or related to, oxidative stress, or [any] a
disease caused by activated oxygen, comprising [the
administration] administering to a mammal in need thereof [an] a
pharmaceutically effective, non-toxic dose of a peptide [encoded

by the polynucleotide sequence of claim 49] comprising the amino acid sequence consisting essentially of amino acid numbers 1 to 526 of SEQ ID NO: 12, and which catalyzes the reduction of dichloroindophenol and oxidized glutathione.

63. (Amended) A method for the prophylaxis or treatment of arteriosclerosis, diabetes, ischemic disorders, edema, vascular hyperpermeability, inflammation, gastric mucosa disorders, acute pancreatitis, Crohn's disease, ulcerative colitis, liver disorders, Paraquat's disease, pulmonary emphysema, chemocarcinogenesis, carcinogenic metastasis, adult respiratory distress syndrome, disseminated intravascular coagulation, cataracts, premature retinopathy, auto-immune diseases, porphyremia, hemolytic diseases, Mediterranean anemia, Parkinson's disease, Alzheimer's disease, epilepsy, ultraviolet radiation disorders, radioactive disorders, frostbite or burns, comprising [the administration] administering to a mammal in need thereof [an] a pharmaceutically effective, non-toxic dose of a peptide [encoded by the polynucleotide sequence of claim 49] which comprises the amino acid sequence consisting essentially of amino acid numbers 1 to 526 of SEQ ID NO: 12, and which catalyzes the reduction of dichloroindophenol and oxidized glutathione.

71. (Amended) An antibody [or an equivalent thereof,] which specifically recognizes KM31-7 protein[, or which specifically recognizes a mutant or variant of KM31-7 protein].

73. (Amended) The antibody of claim 71, wherein said antibody [antigenically resembles a human antibody] is humanized.

77. (Amended) A process for the purification of KM31-7 protein comprising [the use of] contacting the antibody of claim 71 with a suspension containing KM31-7 protein to bind said protein.

80. (Amended) A polypeptide comprising the sequence [given by] consisting essentially of residues 4 to 437 [in sequence] of SEQ ID [number] NO: 2 [, or a mutant or variant thereof].

Attorney Docket No. 950376D1/HG

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Applicant(s): Tohru TAKAHASHI et al.
Serial No. : (Divisional Appln. of
Ser. No. 09/167,151)
Filed : Concomitantly Herewith
For : EXPRESSION SYSTEMS
UTILIZING AUTOLYZING
FUSION PROTEINS AND A
NOVEL REDUCING POLYPEPTIDE

Art Unit :

Examiner :

Express Mail Mailing Label
No.: EL 797 449 111 US
Date of Deposit: April 25, 2001
I hereby certify that this paper is
being deposited with the United
States Postal Service "Express Mail
Post Office to Addressee" service
under 37 CFR 1.10 with sufficient
postage on the date indicated above
and is addressed to the Assistant
Commissioner for Patents,
Washington, D.C. 20231


Dorothy DeFrancesco

In the event that this Paper is late
filed, and the necessary petition
for extension of time is not filed
concurrently herewith, please
consider this as a Petition for the
requisite extension of time, and to
the extent not tendered by check
attached hereto, authorization to
charge the extension fee, or any
other fee required in connection
with this Paper
to Account No. 06-1378.

LETTER TO THE OFFICIAL DRAFTSPERSON


Assistant Commissioner for Patents
Washington, D.C. 20231

S I R :

Fig. 12 was amended to separately label Figs. 12A
and 12B. A red inked, marked up copy of Fig. 12 is enclosed.

Submitted herewith are 13 sheets of Formal Drawings
containing Figs. 1 to 13. Please substitute the enclosed
drawings for Figs. 1 to 13 as originally in the grandparent
application Serial No. 08/500,635.

Respectfully submitted,



RICHARD S. BARTH
REG. NO. 28,180

FRISHAUF, HOLTZ, GOODMAN, LANGER & CHICK, P.C.
767 THIRD AVENUE - 25TH FLOOR
NEW YORK, NEW YORK 10017-2023
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
RSB/ddf

Encs.: (1) Formal Drawings for Figs. 1 to 13 (thirteen sheets)
(2) Red inked, marked up copy of Fig. 12

U.S. PTO
09/842347
04/25/01

202240 4424860




FIG. 12A




FIGURE 12B